If you have been searching for retatrutide and keep landing on pages that feel like they are selling you something, that frustration makes sense. This is an independent guide. It does not sell retatrutide and it is not affiliated with Eli Lilly. It explains what retatrutide actually is, where it stands legally and medically, and how eligible US adults can explore currently available clinician-led GLP-1 options through Hume Care.
Independent educational guide. Not affiliated with Eli Lilly. Hume Care does not provide retatrutide.
Affiliate disclosure: we may earn a commission if you complete the Hume Care assessment.
At a Glance
Topic
Retatrutide
Current Status
Investigational (Phase 3 trials)
Format Discussed
Once-weekly injection
Page Type
Independent editorial review
CTA Destination
Hume Care assessment
Availability Note
US only; state coverage applies
Retatrutide is an investigational once-weekly injectable drug being studied for weight management and metabolic health, currently in Phase 3 clinical trials developed by Eli Lilly.
What separates it from most drugs in this category is the mechanism. Most existing weight-management injectables target one or two hormonal pathways. Retatrutide targets three: GLP-1, GIP, and glucagon. That triple-receptor approach is what has drawn significant attention from researchers watching the trial data.
It is not available as a standard retail product. You cannot simply order it like a supplement. Any website that implies otherwise is either misrepresenting what they are selling or operating in a legally and medically risky area.
This site does not sell retatrutide. For a deeper explanation, see our guide on what retatrutide is.
No. Retatrutide is not FDA approved as of 2026. It is still in Phase 3 clinical trials. That distinction matters enormously when evaluating anything you find online about it.
Any website that implies you can simply purchase retatrutide as a normal consumer product is either describing something different, misrepresenting what they are selling, or operating in a space that carries serious legal and health risk. Investigational drugs are not the same as approved medications.
If you see a site that calls retatrutide "available now" without explaining its investigational status, treat that as a warning sign. For a full breakdown, see our retatrutide FDA approval status page.
Retatrutide remains investigational and is not available as an approved weight-loss medication. Adults who want support now can instead explore currently available GLP-1 weight-management options through a licensed clinician.
Hume Care provides an online eligibility assessment and connects eligible US adults with an independent clinical network. A licensed clinician decides whether treatment is appropriate and what, if anything, may be prescribed.
Answer initial questions online to see whether the Hume Care programme may be available to you.
Any treatment decision is made by an independently licensed clinician based on your health information.
The assessment concerns available GLP-1 weight-management options. It is not an application for retatrutide.
Important: Hume Care does not provide retatrutide. The service is limited to the United States and only to states with clinical coverage. Completing the assessment does not guarantee eligibility, a prescription, a particular medication, or results.
Affiliate link. We may earn a commission if you proceed. Hume Care is separate from this website and from Eli Lilly.
This site is an independent editorial review and referral resource. It was built to help people who are researching retatrutide understand what it is before they make any decisions.
Affiliate disclosure: the referral link on this page connects to Hume Care. If you proceed through the assessment, this site may earn a commission at no extra cost to you. Hume Care is a separate service, and this site does not control eligibility, clinical decisions, prescriptions, fulfilment, pricing, or results.
To be explicit: this site is not affiliated with Eli Lilly. It is not the official retatrutide website. It does not sell retatrutide. Eli Lilly does not operate this page.
The affiliate link connects to the Hume Care eligibility flow for available GLP-1 options, not a retatrutide checkout page. See our full affiliate disclosure for more detail.
The referral link connects you to Hume Care’s online eligibility and clinical intake process, not a retatrutide product checkout. The process generally involves:
Provide your location and basic details so the platform can check whether service coverage is available in your state.
Complete health and medication questions for review by an independently licensed clinician.
If clinically eligible, the clinician determines whether an available GLP-1 treatment option may be appropriate.
A prescription is never guaranteed. You decide whether to continue after reviewing the available information and terms.
State availability may vary. See our page on how telehealth intake works.
Retatrutide works by activating three hormone receptors at once. To understand why that matters, it helps to know what each one does.
GLP-1 (glucagon-like peptide-1) slows digestion and reduces appetite. It is the same pathway targeted by drugs like semaglutide and tirzepatide.
GIP (glucose-dependent insulinotropic polypeptide) supports insulin response and appears to play a role in fat storage and metabolism.
Glucagon raises blood sugar and increases energy expenditure by encouraging the body to burn stored fat, adding a third dimension to the mechanism.
Combining all three in a single weekly injection is the core of what retatrutide does differently. Trial data has shown significant weight reduction in participants. But trial data is not the same as approved outcomes. Do not read the trial numbers as a purchase pitch.
Anyone with a history of thyroid cancer or multiple endocrine neoplasia should not consider retatrutide without speaking directly with a specialist first. People taking medications that affect blood sugar, appetite, or hormonal function need to think carefully about interactions. Retatrutide is not appropriate for use during pregnancy or while breastfeeding based on current available information. Anyone with a serious chronic condition, including heart disease, kidney disease, or liver conditions, should have a thorough clinical conversation before exploring any weight-management injectable. Self-diagnosis and self-prescription are genuinely dangerous here. A licensed clinician is not a box to check. They are the entire process.
Retatrutide's safety profile is still being established through clinical trials. That is a statement of where things actually stand, not a dismissal of the research.
The side effects reported in trials so far are broadly consistent with other GLP-1 class drugs:
Because retatrutide is still investigational, the full picture of who experiences which side effects, at what severity, and under what conditions is not complete. For more detail, see our retatrutide side effects page.
This is probably the most practically useful section on this page. Use this checklist when evaluating any site you land on:
Clear FDA Status DisclosureDoes the site clearly state that retatrutide is not FDA approved? If not, that is a problem.
Defined Offer TypeDoes the site clearly explain whether it is a referral, a direct sale, or a telehealth intake? Blurred lines are a red flag.
Affiliate Disclosure PresentIs the affiliate relationship stated openly? If not, the site may not be operating transparently.
No Official Brand ClaimsDoes the site claim to be official Eli Lilly? If yes, it is not telling the truth.
No Impossible PromisesAre specific outcome guarantees promised without sourcing? That is a significant warning sign.
Seller Identity Is ClearCan you identify who is actually selling or referring, with verifiable contact information?
For more, see our full retatrutide legitimacy checklist.
| Page Type | Approval Transparency | Offer Clarity | Clinician Process |
|---|---|---|---|
| This independent editorial guide | Clear | Referral only | Described accurately |
| Direct miracle-claim pages | Often missing | Checkout disguised as review | Usually none |
| Generic supplement funnels | Not applicable or false | Product sale framing | None |
| Clinician-led intake pages | Generally clear | Intake process described | Core of the offer |
For a structured breakdown, see our clinician-led weight management options page.
No. Retatrutide is not FDA approved as of 2026. It is in Phase 3 clinical trials. Any claim to the contrary is inaccurate. See our full FDA status page for detail.
No. Hume Care does not provide retatrutide. The referral link is for an eligibility assessment concerning currently available clinician-led GLP-1 weight-management options.
The service is intended for adults in the United States where clinical coverage is available. Eligibility, treatment suitability, and any prescription decision are made by an independently licensed clinician.
Retatrutide is not available as a standard retail product. Retatrutide is not available as a standard retail product. The Hume Care referral is for an assessment of currently available GLP-1 options, not for retatrutide. Availability depends on US state coverage and clinical eligibility.
No. This site does not sell retatrutide. It is an independent educational review and referral resource. Clicking the referral link opens Hume Care’s eligibility assessment for currently available GLP-1 options. It does not provide access to retatrutide.
No. This is not an official website. It has no affiliation with Eli Lilly, which develops retatrutide. Eli Lilly does not operate this page.
You are taken to Hume Care’s online assessment. You provide health and medication information, state coverage is checked, and an independent licensed clinician reviews clinical eligibility. A prescription is not guaranteed.
Retatrutide is a real investigational drug being studied by Eli Lilly in Phase 3 clinical trials. It is not a scam. Some websites offering products they call retatrutide may be misrepresenting what they are selling. The molecule itself is real and being actively studied.
Yes. All investigational drugs carry risk, and retatrutide's full safety profile is still being established. Common side effects reported in trials include nausea, vomiting, and gastrointestinal discomfort. A clinician should be part of any evaluation. See our side effects page.
You complete an intake form with health and personal information. A licensed clinician reviews it. If you meet eligibility criteria and services are available in your state, the clinician will discuss options with you directly. You are not automatically enrolled in anything. See our telehealth intake guide.
Yes. Telehealth services vary by state. The intake platform will confirm availability when you submit your information. Not all locations qualify.
A product checkout sells you something directly. A telehealth intake collects health information so a clinician can determine whether any option is appropriate for you. One is a transaction. The other is a medical screening process.
No. This site has no affiliation with Eli Lilly and does not represent the company in any capacity. Eli Lilly has no involvement in this page or its content.
Look for clear disclosure of affiliate relationships, an honest statement of FDA approval status, a described clinician process rather than a simple checkout, and no claims of being an official brand site. See our full legitimacy checklist.
GLP-1 is a hormone that slows digestion and reduces appetite. It is one of three receptors that retatrutide targets. The others are GIP and glucagon. Targeting all three at once in a single weekly injection is what makes retatrutide mechanistically different from most existing weight-management drugs.
No. Semaglutide targets GLP-1 only. Tirzepatide targets GLP-1 and GIP. Retatrutide targets all three: GLP-1, GIP, and glucagon. It is a different molecule at a different and earlier stage of development.
People with a history of thyroid cancer, multiple endocrine neoplasia, serious chronic conditions, or those who are pregnant or breastfeeding should speak with a specialist before exploring any option in this category. Self-assessment is not enough here.
Eligible US adults can use Hume Care’s online assessment to explore currently available clinician-led GLP-1 weight-management options.
Hume Care does not provide retatrutide. US availability and clinical eligibility apply. Completing the assessment does not guarantee treatment or a prescription.
Affiliate disclosure: we may earn a commission if you proceed through the referral link.
Retatrutide is a real investigational drug with a genuinely different mechanism, real clinical trial data, and serious pharmaceutical backing. It is not a supplement, not a miracle product, and not available as a standard retail purchase.
This site exists to explain that clearly. It is an independent editorial resource. It is not affiliated with Eli Lilly. It does not sell retatrutide. The referral link connects to Hume Care so eligible US adults can explore currently available clinician-led GLP-1 options. Hume Care does not offer retatrutide.
If you are in the right situation, that intake path is worth understanding. If you are not, this page has given you enough to evaluate the next site you land on a lot more carefully.
What retatrutide is: An investigational once-weekly injectable drug being studied for weight management and metabolic health, targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly. Currently in Phase 3 clinical trials.
Current status: Not FDA approved as of 2026. Not available as a standard retail product.
What this site offers: An independent educational review and telehealth intake referral. The affiliate link connects to Hume Care for an eligibility assessment involving currently available clinician-led GLP-1 options. Hume Care does not provide retatrutide, and this site does not sell it.
Who the referral path is for: US adults who want to explore currently available clinician-led GLP-1 weight-management options and understand that state coverage and clinical eligibility apply.
Non-affiliation notice: This website is not affiliated with Eli Lilly. It is not the official retatrutide website. Eli Lilly does not operate or endorse this page.